Covidien Unveils Advanced Ablation Device for Liver Tumor - Analyst Blog

By
A A A

Aiming to capitalize on the opportunities in the inoperable liver cancer market, Covidien plc ( COV ) unveiled Emprint Ablation System with Thermosphere Technology - an advanced ablation system designed to precisely heat and destroy diseased soft tissue in the liver, lungs and kidney.

The Emprint Ablation System enables physicians to deliver precise ablation directly to soft tissue, including liver tumors. This innovative technology ensures more certainty regardless of the target location or tissue type, thus making liver tumor ablation more accurate.

Covidien's Ablation System provides clinicians with three kinds of spatial energy control - thermal, field and wavelength. This helps them to create predictable and spherical ablation zones regardless of target location, tissue type or changes in tissue properties during a procedure.


By providing predictable spherical ablation zones, this technology offers physicians more choices in terms of approach, further simplifying needle placement and saving planning and procedure time.

A liver tumor ablation procedure destroys the tumor without removing it, thus providing an alternative to open surgery resection or other treatments. This method is ideal for patients for whom surgical removal of tumors is not an optimal solution.

With Covidien's Ablation System, physicians can treat liver tumor by non-surgical procedures. They utilize ultrasound or CT scanning to guide the system's antenna and insert it directly into the tumor through the skin. Apart from non-surgical procedures, Covidien's advanced ablation system can also be used for minimally invasive surgery and open surgery.

In Apr 2014, Covidien received the U.S. Food and Drug Administration 510(k) clearance for its Emprint Ablation System. In addition, the company completed all European requirements for attaining the CE Mark for the product. Covidien expects to fully launch the Emprint Ablation System in the U.S. and the European Union in the present quarter.

Currently, Covidien carries a Zacks Rank #4 (Sell). Better-ranked stocks in the medical products industry include Alere Inc. ( ALR ), CareFusion Corporation ( CFN ) and Wright Medical Group Inc. ( WMGI ). All these stocks carry a Zacks Rank #2 (Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

COVIDIEN PLC (COV): Free Stock Analysis Report

WRIGHT MEDICAL (WMGI): Free Stock Analysis Report

CAREFUSION CORP (CFN): Free Stock Analysis Report

ALERE INC (ALR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: COV , WMGI , CFN , ALR

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

64,655,493
  • $17.88 ▼ 1.38%
53,363,101
  • $18.51 ▼ 6.98%
42,789,793
  • $94.01 ▼ 1.26%
40,818,762
  • $121.30 ▼ 0.87%
38,086,152
  • $23.28 ▼ 9.17%
36,103,930
  • $14.20 ▼ 0.77%
31,870,696
  • $14.83 ▼ 1.79%
29,019,850
  • $46.70 ▼ 0.38%
As of 7/31/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com